药物临床试验登记与信息公示平台数据显示,轩竹生物科技股份有限公司/山东轩竹医药科技有限公司的评估XZP - 7797 - H1治疗晚期实体瘤受试者的安全性、耐受性、药代动力学特征和初步疗效的开放、多中心I期临床研究已启动。临床试验登记号为CTR20253913,首次公示信息日期为2025年10月11日。该药物剂型为片剂,用法为温水送服,需空腹给药,在每次给药前至少2小时以及给药后1小时内禁食。拟定...
Source Link药物临床试验登记与信息公示平台数据显示,轩竹生物科技股份有限公司/山东轩竹医药科技有限公司的评估XZP - 7797 - H1治疗晚期实体瘤受试者的安全性、耐受性、药代动力学特征和初步疗效的开放、多中心I期临床研究已启动。临床试验登记号为CTR20253913,首次公示信息日期为2025年10月11日。该药物剂型为片剂,用法为温水送服,需空腹给药,在每次给药前至少2小时以及给药后1小时内禁食。拟定...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.